madman
Super Moderator
Much more to the story here!
* Longer-term studies are still needed to determine whether testosterone therapy is safe with respect to cardiovascular, thromboembolic, and prostatic diseases. However, recent placebo-controlled trials (of 1-4 years) of TRT offer reassurance about the risk of cardiovascular and prostate disease (prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia, although less so for pulmonary emboli and thrombotic risk. Because the recent placebo-controlled trials of TRT excluded men at high risk of thromboembolic and prostatic disease, shorter studies (1-5 years) of typical mid- and high-normal range testosterone dosages used clinically must be performed in men with low serum testosterone and at high risk for these diseases. Placebo-controlled-studies with typical mid-range and high-range testosterone dosages for men with low serum testosterone with follow-up for up to 10, 15 and 20 years must be done to determine long-term risks of testosterone therapy for cardiovascular and prostatic disease.
www.endocrine.org
* Longer-term studies are still needed to determine whether testosterone therapy is safe with respect to cardiovascular, thromboembolic, and prostatic diseases. However, recent placebo-controlled trials (of 1-4 years) of TRT offer reassurance about the risk of cardiovascular and prostate disease (prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia, although less so for pulmonary emboli and thrombotic risk. Because the recent placebo-controlled trials of TRT excluded men at high risk of thromboembolic and prostatic disease, shorter studies (1-5 years) of typical mid- and high-normal range testosterone dosages used clinically must be performed in men with low serum testosterone and at high risk for these diseases. Placebo-controlled-studies with typical mid-range and high-range testosterone dosages for men with low serum testosterone with follow-up for up to 10, 15 and 20 years must be done to determine long-term risks of testosterone therapy for cardiovascular and prostatic disease.
Society Submits Comments to FDA Expert Panel on Testosterone Replacement Therapy for Men
The Endocrine Society submitted comments on February 6 to the Food and Drug Administration (FDA) Expert Panel on Testosterone Replacement Therapy for Men.
www.endocrine.org
